glp-1 drugs medicare Bridge Program: What Medicare Beneficiaries Need to Know | Plan Medicare Medicare will now help pay

Takeaways Given the concerns about retinopathy progression, internists may also seek input from optometrists on whether GLP-1/GIP agonists should be prescribed in patients with existing retinopathy

[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., Brown T.J., Streutker C., Holland D., Cao X., Baggio L.L., et al

Eur J Med Chem

In a large phase 3 obesity trial (ACHIEVE-1), orforglipron at daily doses of 3, 12 and 36 mg caused approximately: Diarrhoea: 1926% of participants (vs 9% on placebo) Nausea: 1318% (vs 2% on placebo) Constipation: 817% (vs 4% on placebo) Vomiting: 514% (vs 1% on placebo) Across multiple studies, 617% of people stopped treatment because of side effects, mostly gut-related symptoms

Take the First Step If youre ready to discover if GLP-1 medications are right for you, we encourage you to take our free assessment quiz here

Willow Program Snapshot 3